Singapore-based biotechnology company MiRXES has raised $77 million in Series C funding led by CR-CP Life Science Fund, a joint venture between China Resources Group and Thailand’s Charoen Pokphand Group.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
